184 related articles for article (PubMed ID: 34641952)
21. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.
Liu X; Wang Y; Benaissa S; Matsuda A; Kantarjian H; Estrov Z; Plunkett W
Blood; 2010 Sep; 116(10):1737-46. PubMed ID: 20479284
[TBL] [Abstract][Full Text] [Related]
22. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.
Green SR; Choudhary AK; Fleming IN
Br J Cancer; 2010 Oct; 103(9):1391-9. PubMed ID: 20924380
[TBL] [Abstract][Full Text] [Related]
23. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
[TBL] [Abstract][Full Text] [Related]
24. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
Yoshida K; Fujita A; Narazaki H; Asano T; Itoh Y
Cancer Chemother Pharmacol; 2022 Jan; 89(1):83-91. PubMed ID: 34825941
[TBL] [Abstract][Full Text] [Related]
25. Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.
Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CB; Sandhow L; Kutzner J; Hed Myrberg I; Bunten SS; Axelsson H; Zhang SM; Rasti A; Mäkelä P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtiö J; Rassidakis GZ; Pokrovskaja Tamm K; Warpman-Berglund U; Heyman M; Grandér D; Lehmann S; Lundbäck T; Qian H; Henter JI; Schaller T; Helleday T; Herold N
EMBO Mol Med; 2020 Mar; 12(3):e10419. PubMed ID: 31950591
[TBL] [Abstract][Full Text] [Related]
26. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Liu X; Guo Y; Li Y; Jiang Y; Chubb S; Azuma A; Huang P; Matsuda A; Hittelman W; Plunkett W
Cancer Res; 2005 Aug; 65(15):6874-81. PubMed ID: 16061671
[TBL] [Abstract][Full Text] [Related]
27. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
[TBL] [Abstract][Full Text] [Related]
28. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.
Galmarini CM; Thomas X; Calvo F; Rousselot P; Rabilloud M; El Jaffari A; Cros E; Dumontet C
Br J Haematol; 2002 Jun; 117(4):860-8. PubMed ID: 12060121
[TBL] [Abstract][Full Text] [Related]
29. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1.
Knecht KM; Buzovetsky O; Schneider C; Thomas D; Srikanth V; Kaderali L; Tofoleanu F; Reiss K; Ferreirós N; Geisslinger G; Batista VS; Ji X; Cinatl J; Keppler OT; Xiong Y
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10022-E10031. PubMed ID: 30305425
[TBL] [Abstract][Full Text] [Related]
30. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277
[TBL] [Abstract][Full Text] [Related]
31. Characterization of newly established human myeloid leukemia cell line (KF-19) and its drug resistant sublines.
Fukuda T; Kamishima T; Kakihara T; Ohnishi Y; Suzuki T
Leuk Res; 1996; 20(11-12):931-9. PubMed ID: 9009251
[TBL] [Abstract][Full Text] [Related]
32. Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML.
Zhang F; Sun J; Tang X; Liang Y; Jiao Q; Yu B; Dai Z; Yuan X; Li J; Yan J; Zhang Z; Fan S; Wang M; Hu H; Zhang C; Lv XB
Cell Death Dis; 2022 Jul; 13(7):590. PubMed ID: 35803902
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
Freiburghaus C; Emruli VK; Johansson A; Eskelund CW; Grønbæk K; Olsson R; Ek F; Jerkeman M; Ek S
BMC Cancer; 2018 Apr; 18(1):466. PubMed ID: 29695239
[TBL] [Abstract][Full Text] [Related]
34. FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia.
Perelló-Reus CM; Català A; Caviedes-Cárdenas L; Vega-García N; Camós M; Pérez-Torras S; Pastor-Anglada M
Pharmacol Res; 2020 Jan; 151():104556. PubMed ID: 31778791
[TBL] [Abstract][Full Text] [Related]
35. Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells.
Adema AD; Zuurbier L; Floor K; Hubeek I; Kaspers GJ; Albertoni F; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):981-6. PubMed ID: 17065050
[TBL] [Abstract][Full Text] [Related]
36. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.
Veuger MJ; Honders MW; Willemze R; Barge RM
Eur J Haematol; 2002 Sep; 69(3):171-8. PubMed ID: 12406011
[TBL] [Abstract][Full Text] [Related]
37. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.
Galmarini CM; Thomas X; Graham K; El Jafaari A; Cros E; Jordheim L; Mackey JR; Dumontet C
Br J Haematol; 2003 Jul; 122(1):53-60. PubMed ID: 12823345
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
39. Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
Anticancer Res; 2014 Apr; 34(4):1657-62. PubMed ID: 24692694
[TBL] [Abstract][Full Text] [Related]
40. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside.
Flasshove M; Strumberg D; Ayscue L; Mitchell BS; Tirier C; Heit W; Seeber S; Schütte J
Leukemia; 1994 May; 8(5):780-5. PubMed ID: 7514246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
